Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023
May 02 2023 - 4:01PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections, today announced that it plans to report its
financial results for its fiscal second quarter ended March 31,
2023 after the U.S. market closes on May 8, 2023. Enanta management
will host a conference call at 4:30 p.m. ET to discuss these
results and provide an update on Enanta’s business, including its
research and development pipeline.
Conference Call and Webcast Information The live webcast
can be accessed under "Events & Presentations" in the investors
section of Enanta’s website. To join by phone, participants can
register for the call here. It is recommended that participants
register a day in advance or at a minimum of 15 minutes before the
call. Once registered, participants will receive an email with the
dial-in information. The archived webcast will be available on
Enanta’s website for approximately 30 days following the event.
About Enanta Pharmaceuticals, Inc. Enanta is using its
robust, chemistry-driven approach and drug discovery capabilities
to become a leader in the discovery and development of small
molecule drugs for the treatment of viral infections. Enanta’s
research and development programs include clinical candidates for
the following disease targets: respiratory syncytial virus (RSV),
SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also
conducting research on a single agent targeting both RSV and human
metapneumovirus (hMPV).
Enanta’s receives royalties from hepatitis C virus (HCV)
products developed under its collaboration with AbbVie.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of
one of the leading treatment regimens for curing chronic HCV
infection and is sold by AbbVie in numerous countries under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230502006056/en/
Media and Investors Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024